Abstract
Congenital analbuminaemia, a rare disorder associated with defective albumin synthesis, is characterised by hyperlipidaemia. Administration of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGRI) to analbuminaemic rats have demonstrated no significant effect on plasma lipids, however no published information regarding HMGRI treatment could be found in human subjects. The efficacy, safety and tolerability of Simvastatin was thus investigated in 2 South African patients with analbuminaemia, a 21 year old Caucasian male (H-B) and a 61 year old black male (A-K). In the case of A-K, the lipid profile responded predictably but H-B responded less that expected from general experience with Simvastatin. Both subjects, however, experienced a three- to five-fold increase in creatine kinase. The use of HMGRI's should thus be used cautiously in these patients and it may be advisable to reserve treatment for secondary prevention.
References
Kaysen GA. Nephrotic hyperlipidaemia: Primary abnormalities in both lipoprotein catabolism and synthesis. Miner Electrolyte Metab 1992; 18: 212-216.
Marsh JB. Lipoprotein metabolism in experimental nephrosis. J Lipid Res 1984; 25: 1619-1623.
Rabelink AJ. Hené RJ, Erkelens DW, Joles JA, Koomans HA. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. Lancet 1988; ii: 1335-1338.
Van Tol A, Jansen EH, Koomans HA, Joles JA. Hyperlipoproteinaemia in Nagase analbuminaemic rats: Effects of pravastatin on plasma (apo)lipoprotein and lecithin: Cholesterol acyltransferase activity. J Lipid Res 1991; 32(11): 1719-1728.
Joles J, Willekes-Koolschijn N, Koomans H, et al. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats. Lab Anim 1992; 26(4): 269-280.
Berger GMB, Stephen CR, Finestone A, Beatty DW. Analbuminaemia. Clinical and laboratory features in a South African patient. S Afr Med J 1985; 67: 418-422.
The Simvastatin Pravastain Study Group. Comparision of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolaemia. Am J Cardiol 1993; 71: 1408-1414.
Boccuzzi SJ, Bocanegra TS, Walker JF, Shapiro DR, Keegan ME. Long-term safety and efficacy profile of simvastatin. Am J Cardiol 1991; 68: 1127-1131.
Beer MH, Berkow R, eds. The Merck Manual of Diagnosis and Therapy. 17th ed. New Jersey, USA: The Merck Publishing Group, 1999: 2556-2566.
Piroli RJ, Passananti Th, Shively CA, Vewell ES. Antipyrine and warfarin disposition in a patient with idiopathic hypoalbuminaemia. Clin Pharmacol Ther 1981; 30: 810-816.
Plosker GL, McTavish D. Simvastatin. Reappraisal of the pharmacology and therapeutic efficacy in hypercholesterolaemia. Drugs 1995; 50: 334-336.
Kallee E. Bennhold's analbuminemia: A follow-up study of the first two cases (1953-1992). J Lab Clin Med 1996; 127: 470-480.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Burgess, L.J., Marais, A.D. The Use of Simvastatin in Analbuminaemia. Cardiovasc Drugs Ther 15, 555–558 (2001). https://doi.org/10.1023/A:1013780007561
Issue Date:
DOI: https://doi.org/10.1023/A:1013780007561